Noom Enters Longevity Health Space with Proactive Health Microdose GLP-1Rx Program Designed to Help Millions Address the Biomarkers Most Linked to Future Disease

New program pairs microdoses of GLP-1 medication with Noom's powerful behavior-change program and at-home biomarker testing to track the health impact of combining GLP-1 therapy with healthy habits.
Le Lézard

Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP?1 and amylin analogues for weight management

Today, Novo Nordisk announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) ...